SCYNEXIS, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
SCYNEXIS, Inc. (SCYX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$5.39 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2025-05-15
- SCYNEXIS, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-03-31 was -$5.39M, a 1411.68% decline year-over-year.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-12-31 was -$4.43M.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-09-30 was -$2.81M.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-06-30 was -$14.46M, a 111.78% decline year-over-year.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$21.29M, a 131.75% decline from fiscal 2023.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was $67.04M.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$62.81M.
- SCYNEXIS, Inc. net income (loss) available to common stockholders, diluted for fiscal 2016 was -$29.99M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2025-03-31 | -$5.39M 10-Q · filed 2025-05-15 | -$9.82M derived: sum of 2 quarters · filed 2025-05-15 | -$12.63M derived: sum of 3 quarters · filed 2025-05-15 | -$27.09M derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | -$4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$7.24M derived: sum of 2 quarters · filed 2025-03-12 | -$21.70M derived: sum of 3 quarters · filed 2025-03-12 | -$21.29M 10-K · filed 2025-03-12 |
| 2024-09-30 | -$2.81M 10-Q · filed 2024-11-06 | -$17.27M derived: sum of 2 quarters · filed 2024-11-06 | -$16.86M 10-Q · filed 2024-11-06 | -$37.88M derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-06-30 | -$14.46M 10-Q · filed 2024-08-08 | -$14.05M 10-Q · filed 2024-08-08 | -$35.07M derived: sum of 3 quarters · filed 2025-05-15 | -$36.83M derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-03-31 | $411.00K 10-Q · filed 2025-05-15 | -$20.61M derived: sum of 2 quarters · filed 2025-05-15 | -$22.37M derived: sum of 3 quarters · filed 2025-05-15 | $100.32M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$21.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$22.78M derived: sum of 2 quarters · filed 2025-03-12 | $99.91M derived: sum of 3 quarters · filed 2025-03-12 | $67.04M 10-K · filed 2025-03-12 |
| 2023-09-30 | -$1.76M 10-Q · filed 2024-11-06 | $120.94M derived: sum of 2 quarters · filed 2024-11-06 | $88.06M 10-Q · filed 2024-11-06 | $72.63M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $122.69M 10-Q · filed 2024-08-08 | $89.43M 10-Q · filed 2024-08-08 | $74.39M derived: sum of 3 quarters · filed 2024-08-08 | $44.80M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$33.88M 10-Q · filed 2024-05-08 | -$48.30M derived: sum of 2 quarters · filed 2024-05-08 | -$77.89M derived: sum of 3 quarters · filed 2024-05-08 | -$91.23M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$14.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$44.01M derived: sum of 2 quarters · filed 2024-03-28 | -$57.36M derived: sum of 3 quarters · filed 2024-03-28 | -$62.81M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$29.58M 10-Q · filed 2023-11-13 | -$42.93M derived: sum of 2 quarters · filed 2023-11-13 | -$48.38M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$13.35M 10-Q · filed 2023-08-14 | -$18.80M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$6.04M 10-Q · filed 2023-05-10 | |||
| 2021-09-30 | -$1.59M 10-Q · filed 2022-11-09 | -$7.35M derived: sum of 2 quarters · filed 2022-11-09 | -$19.34M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$5.76M 10-Q · filed 2022-08-15 | -$11.76M 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | -$6.00M 10-Q · filed 2022-05-12 | |||
| 2020-09-30 | -$3.74M 10-Q · filed 2021-11-10 | -$10.12M derived: sum of 2 quarters · filed 2021-11-10 | -$15.39M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$6.38M 10-Q · filed 2021-08-16 | -$13.38M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$7.00M 10-Q · filed 2021-05-17 | |||
| 2019-09-30 | -$9.76M 10-Q · filed 2020-11-06 | -$39.25M 10-Q · filed 2020-11-06 | ||
| 2018-09-30 | $351.00K 10-Q · filed 2019-11-12 | -$14.41M 10-Q · filed 2019-11-12 | ||
| 2018-03-31 | -$4.00M 10-Q · filed 2018-05-08 | |||
| 2017-03-31 | -$6.39M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | -$29.99M 10-K · filed 2017-03-13 | |||
| 2016-03-31 | -$7.18M 10-Q · filed 2017-05-08 | -$15.57M derived: sum of 2 quarters · filed 2017-05-08 | -$23.93M derived: sum of 3 quarters · filed 2017-05-08 | -$33.42M derived: sum of 4 quarters · filed 2017-05-08 |
| 2015-12-31 | -$8.39M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$16.74M derived: sum of 2 quarters · filed 2017-03-13 | -$26.24M derived: sum of 3 quarters · filed 2017-03-13 | -$32.62M 10-K · filed 2017-03-13 |
| 2015-09-30 | -$8.36M 10-Q · filed 2015-11-13 | -$17.85M derived: sum of 2 quarters · filed 2015-11-13 | -$24.23M 10-Q · filed 2015-11-13 | -$27.31M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-06-30 | -$9.50M 10-Q · filed 2015-08-19 | -$15.88M 10-Q · filed 2015-08-19 | -$18.96M derived: sum of 3 quarters · filed 2017-03-13 | -$22.76M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-03-31 | -$6.38M 8-K · filed 2015-10-30 | -$9.46M derived: sum of 2 quarters · filed 2017-03-13 | -$13.26M derived: sum of 3 quarters · filed 2017-03-13 | -$18.59M derived: sum of 4 quarters · filed 2017-03-13 |
| 2014-12-31 | -$3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$6.88M derived: sum of 2 quarters · filed 2017-03-13 | -$12.21M derived: sum of 3 quarters · filed 2017-03-13 | -$15.95M 10-K · filed 2017-03-13 |
| 2014-09-30 | -$3.80M 10-Q · filed 2015-11-13 | -$9.13M derived: sum of 2 quarters · filed 2015-11-13 | -$12.87M 10-Q · filed 2015-11-13 | -$51.21M derived: sum of 4 quarters · filed 2015-11-13 |
| 2014-06-30 | -$5.33M 10-Q · filed 2015-08-19 | -$9.37M 10-Q · filed 2015-08-19 | -$47.41M derived: sum of 3 quarters · filed 2015-10-30 | -$51.37M derived: sum of 4 quarters · filed 2015-10-30 |
| 2014-03-31 | -$4.00M 8-K · filed 2015-10-30 | -$42.08M derived: sum of 2 quarters · filed 2015-10-30 | -$46.04M derived: sum of 3 quarters · filed 2015-10-30 | -$48.74M derived: sum of 4 quarters · filed 2015-10-30 |
| 2013-12-31 | -$38.08M derived: 8-K 12 month − 10-Q 9 month · filed 2015-10-30 | -$42.04M derived: sum of 2 quarters · filed 2015-10-30 | -$44.74M derived: sum of 3 quarters · filed 2015-10-30 | -$46.81M 8-K · filed 2015-10-30 |
| 2013-09-30 | -$3.96M 10-Q · filed 2014-11-13 | -$6.66M derived: sum of 2 quarters · filed 2014-11-13 | -$8.73M 10-Q · filed 2014-11-13 | |
| 2013-06-30 | -$2.70M 10-Q · filed 2014-08-13 | -$4.77M 10-Q · filed 2014-08-13 | ||
| 2013-03-31 | -$2.07M 10-Q/A · filed 2014-07-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |